EGFR and non-small cell lung carcinoma: Different than the aforementioned anti-EGFR mAbs, amivantamab is a bispecific antibody that binds simultaneously to the extracellular domains of EGFR and MET, and has been recently approved for the treatment of adult patients with advanced or metastatic NSCLC with EGFR exon 20 insertion mutations (Syed 2021).